NO322292B1 - Primaer emballasje inneholdende en vandig opplosning for parenteral administrasjon, fremgangsmate for fremstilling av emballasjen, og anvendelse av en gummiforsegling for denne - Google Patents
Primaer emballasje inneholdende en vandig opplosning for parenteral administrasjon, fremgangsmate for fremstilling av emballasjen, og anvendelse av en gummiforsegling for denne Download PDFInfo
- Publication number
- NO322292B1 NO322292B1 NO20011032A NO20011032A NO322292B1 NO 322292 B1 NO322292 B1 NO 322292B1 NO 20011032 A NO20011032 A NO 20011032A NO 20011032 A NO20011032 A NO 20011032A NO 322292 B1 NO322292 B1 NO 322292B1
- Authority
- NO
- Norway
- Prior art keywords
- primary packaging
- solution
- packaging according
- rubber
- melagatran
- Prior art date
Links
- 229920001971 elastomer Polymers 0.000 title claims description 45
- 239000005060 rubber Substances 0.000 title claims description 45
- 239000007864 aqueous solution Substances 0.000 title claims description 19
- 238000007911 parenteral administration Methods 0.000 title claims description 3
- 238000000034 method Methods 0.000 title description 3
- 238000004806 packaging method and process Methods 0.000 title description 3
- 239000000243 solution Substances 0.000 claims description 52
- -1 bromobutyl Chemical group 0.000 claims description 39
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 38
- 229960002137 melagatran Drugs 0.000 claims description 38
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical group C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 claims description 38
- 238000009516 primary packaging Methods 0.000 claims description 33
- 229920005557 bromobutyl Polymers 0.000 claims description 32
- 239000000463 material Substances 0.000 claims description 24
- 229940122388 Thrombin inhibitor Drugs 0.000 claims description 22
- 239000003868 thrombin inhibitor Substances 0.000 claims description 22
- 239000011780 sodium chloride Substances 0.000 claims description 19
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims description 15
- 239000011521 glass Substances 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 5
- 229920000858 Cyclodextrin Polymers 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- CDPROXZBMHOBTQ-SJORKVTESA-N 2-[[(2r)-3-cyclohexyl-1-[(2s)-2-[3-(diaminomethylideneamino)propylcarbamoyl]piperidin-1-yl]-1-oxopropan-2-yl]amino]acetic acid Chemical compound NC(N)=NCCCNC(=O)[C@@H]1CCCCN1C(=O)[C@H](NCC(O)=O)CC1CCCCC1 CDPROXZBMHOBTQ-SJORKVTESA-N 0.000 claims description 3
- 229940126062 Compound A Drugs 0.000 claims description 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 3
- 229950003291 inogatran Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229940071643 prefilled syringe Drugs 0.000 claims description 3
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 2
- 125000004494 ethyl ester group Chemical group 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 238000011146 sterile filtration Methods 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 229920005556 chlorobutyl Polymers 0.000 description 15
- 230000015556 catabolic process Effects 0.000 description 6
- 239000007799 cork Substances 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/3129—Syringe barrels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/06—Ampoules or carpules
- A61J1/062—Carpules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1468—Containers characterised by specific material properties
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9802938A SE9802938D0 (sv) | 1998-09-01 | 1998-09-01 | Improved stability for injection solutions |
| PCT/SE1999/001440 WO2000012043A1 (en) | 1998-09-01 | 1999-08-24 | Improved stability for injection solutions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20011032D0 NO20011032D0 (no) | 2001-02-28 |
| NO20011032L NO20011032L (no) | 2001-04-30 |
| NO322292B1 true NO322292B1 (no) | 2006-09-11 |
Family
ID=20412436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20011032A NO322292B1 (no) | 1998-09-01 | 2001-02-28 | Primaer emballasje inneholdende en vandig opplosning for parenteral administrasjon, fremgangsmate for fremstilling av emballasjen, og anvendelse av en gummiforsegling for denne |
Country Status (34)
| Country | Link |
|---|---|
| US (4) | US6576245B1 (et) |
| EP (1) | EP1109526B1 (et) |
| JP (1) | JP2002523184A (et) |
| KR (1) | KR100614162B1 (et) |
| CN (1) | CN1230141C (et) |
| AR (1) | AR033788A1 (et) |
| AT (1) | ATE262882T1 (et) |
| AU (1) | AU754447C (et) |
| BR (1) | BR9913261A (et) |
| CA (1) | CA2340238C (et) |
| CZ (1) | CZ2001743A3 (et) |
| DE (1) | DE69916082T2 (et) |
| DK (1) | DK1109526T3 (et) |
| EE (1) | EE04768B1 (et) |
| ES (1) | ES2217808T3 (et) |
| HK (1) | HK1035482A1 (et) |
| HU (1) | HUP0104161A3 (et) |
| ID (1) | ID28015A (et) |
| IL (2) | IL141333A0 (et) |
| IS (1) | IS2230B (et) |
| MY (1) | MY120822A (et) |
| NO (1) | NO322292B1 (et) |
| NZ (1) | NZ509985A (et) |
| PL (1) | PL195244B1 (et) |
| PT (1) | PT1109526E (et) |
| RU (1) | RU2224499C2 (et) |
| SA (1) | SA99200573B1 (et) |
| SE (1) | SE9802938D0 (et) |
| SK (1) | SK285474B6 (et) |
| TR (1) | TR200100679T2 (et) |
| TW (1) | TWI228987B (et) |
| UA (1) | UA73282C2 (et) |
| WO (1) | WO2000012043A1 (et) |
| ZA (1) | ZA200101590B (et) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9802938D0 (sv) * | 1998-09-01 | 1998-09-01 | Astra Ab | Improved stability for injection solutions |
| US6462021B1 (en) | 2000-11-06 | 2002-10-08 | Astrazeneca Ab | Use of low molecular weight thrombin inhibitor |
| AR035216A1 (es) * | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
| US7129233B2 (en) | 2000-12-01 | 2006-10-31 | Astrazeneca Ab | Mandelic acid derivatives and their use as thrombin inhibitors |
| AR034517A1 (es) * | 2001-06-21 | 2004-02-25 | Astrazeneca Ab | Formulacion farmaceutica |
| US6802828B2 (en) * | 2001-11-23 | 2004-10-12 | Duoject Medical Systems, Inc. | System for filling and assembling pharmaceutical delivery devices |
| SE0201661D0 (sv) * | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | New salts |
| SE0201659D0 (sv) | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | Modified release pharmaceutical formulation |
| DK1569912T3 (en) | 2002-12-03 | 2015-06-29 | Pharmacyclics Inc | 2- (2-hydroxybiphenyl-3-yl) -1h-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors. |
| EA009123B1 (ru) * | 2003-01-14 | 2007-10-26 | Тева Фармасьютикал Индастриз, Лтд. | Парентеральные композиции пептидов для лечения системной красной волчанки |
| KR100505557B1 (ko) * | 2003-02-10 | 2005-08-03 | 조을룡 | 약병마개 제조용 고무 조성물 |
| US7781424B2 (en) * | 2003-05-27 | 2010-08-24 | Astrazeneca Ab | Modified release pharmaceutical formulation |
| US8476010B2 (en) | 2003-07-10 | 2013-07-02 | App Pharmaceuticals Llc | Propofol formulations with non-reactive container closures |
| US7524354B2 (en) * | 2005-07-07 | 2009-04-28 | Research Foundation Of State University Of New York | Controlled synthesis of highly monodispersed gold nanoparticles |
| US20070166187A1 (en) * | 2006-01-18 | 2007-07-19 | Song Jing F | Stabilization of paricalcitol using chlorobutyl or chlorinated butyl stoppers |
| TW200827336A (en) * | 2006-12-06 | 2008-07-01 | Astrazeneca Ab | New crystalline forms |
| US20090061000A1 (en) * | 2007-08-31 | 2009-03-05 | Astrazeneca Ab | Pharmaceutical formulation use 030 |
| US8939943B2 (en) | 2011-01-26 | 2015-01-27 | Kaleo, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
| US8627816B2 (en) | 2011-02-28 | 2014-01-14 | Intelliject, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
| KR20140082723A (ko) * | 2011-09-27 | 2014-07-02 | 벡톤 디킨슨 프랑스 | 의료 주사 장치에서 코팅물로서 플라즈마 처리된 실리콘 오일의 용도 |
| US9517307B2 (en) | 2014-07-18 | 2016-12-13 | Kaleo, Inc. | Devices and methods for delivering opioid antagonists including formulations for naloxone |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4381779A (en) | 1981-07-16 | 1983-05-03 | Sterling Drug Inc. | Deformable slidable piston to provide self-aspiration in hypodermic cartridge ampoules |
| DK0390244T3 (da) * | 1989-03-28 | 1993-02-08 | Duphar Int Res | Forfyldt injektionsanordning omfattende en cylinder, hvori en væskeformig diazepamformulering er in-desluttet |
| SE9103612D0 (sv) | 1991-12-04 | 1991-12-04 | Astra Ab | New peptide derivatives |
| SE9301916D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptides derivatives |
| SE9402332D0 (sv) * | 1994-07-01 | 1994-07-01 | Pharmacia Ab | Igf-1 |
| SE9501472D0 (sv) | 1995-04-21 | 1995-04-21 | Pharmacia Ab | Truncated IGF-I |
| SA96170106A (ar) | 1995-07-06 | 2005-12-03 | أسترا أكتيبولاج | مشتقات حامض أميني جديدة |
| TWI238827B (en) | 1995-12-21 | 2005-09-01 | Astrazeneca Ab | Prodrugs of thrombin inhibitors |
| SE9601556D0 (sv) | 1996-04-24 | 1996-04-24 | Astra Ab | New pharmaceutical formulation of a thrombin inhibitor for parenteral use |
| SE9802938D0 (sv) | 1998-09-01 | 1998-09-01 | Astra Ab | Improved stability for injection solutions |
-
1998
- 1998-09-01 SE SE9802938A patent/SE9802938D0/xx unknown
-
1999
- 1999-08-18 AR ARP990104129 patent/AR033788A1/es active IP Right Grant
- 1999-08-20 TW TW088114257A patent/TWI228987B/zh not_active IP Right Cessation
- 1999-08-24 CZ CZ2001743A patent/CZ2001743A3/cs unknown
- 1999-08-24 HU HU0104161A patent/HUP0104161A3/hu unknown
- 1999-08-24 PL PL99346471A patent/PL195244B1/pl not_active IP Right Cessation
- 1999-08-24 TR TR200100679T patent/TR200100679T2/xx unknown
- 1999-08-24 BR BR9913261A patent/BR9913261A/pt not_active IP Right Cessation
- 1999-08-24 PT PT99946504T patent/PT1109526E/pt unknown
- 1999-08-24 DE DE1999616082 patent/DE69916082T2/de not_active Expired - Lifetime
- 1999-08-24 WO PCT/SE1999/001440 patent/WO2000012043A1/en active IP Right Grant
- 1999-08-24 IL IL14133399A patent/IL141333A0/xx active IP Right Grant
- 1999-08-24 ES ES99946504T patent/ES2217808T3/es not_active Expired - Lifetime
- 1999-08-24 NZ NZ50998599A patent/NZ509985A/xx not_active IP Right Cessation
- 1999-08-24 AT AT99946504T patent/ATE262882T1/de not_active IP Right Cessation
- 1999-08-24 JP JP2000567167A patent/JP2002523184A/ja active Pending
- 1999-08-24 CA CA 2340238 patent/CA2340238C/en not_active Expired - Fee Related
- 1999-08-24 EE EEP200100131A patent/EE04768B1/et not_active IP Right Cessation
- 1999-08-24 EP EP99946504A patent/EP1109526B1/en not_active Expired - Lifetime
- 1999-08-24 RU RU2001104425A patent/RU2224499C2/ru not_active IP Right Cessation
- 1999-08-24 KR KR1020017002618A patent/KR100614162B1/ko not_active IP Right Cessation
- 1999-08-24 CN CNB998101931A patent/CN1230141C/zh not_active Expired - Fee Related
- 1999-08-24 DK DK99946504T patent/DK1109526T3/da active
- 1999-08-24 ID ID20010430A patent/ID28015A/id unknown
- 1999-08-24 SK SK282-2001A patent/SK285474B6/sk not_active IP Right Cessation
- 1999-08-24 US US09/423,185 patent/US6576245B1/en not_active Expired - Fee Related
- 1999-08-24 AU AU58903/99A patent/AU754447C/en not_active Ceased
- 1999-08-24 UA UA2001021045A patent/UA73282C2/uk unknown
- 1999-08-30 MY MYPI9903750 patent/MY120822A/en unknown
- 1999-09-14 SA SA99200573A patent/SA99200573B1/ar unknown
-
2001
- 2001-02-08 IL IL141333A patent/IL141333A/en not_active IP Right Cessation
- 2001-02-15 IS IS5845A patent/IS2230B/is unknown
- 2001-02-26 ZA ZA200101590A patent/ZA200101590B/xx unknown
- 2001-02-28 NO NO20011032A patent/NO322292B1/no not_active IP Right Cessation
- 2001-08-23 HK HK01105969A patent/HK1035482A1/xx not_active IP Right Cessation
-
2003
- 2003-01-17 US US10/347,046 patent/US6660279B2/en not_active Expired - Fee Related
- 2003-10-15 US US10/687,540 patent/US6998136B2/en not_active Expired - Fee Related
-
2005
- 2005-11-08 US US11/270,309 patent/US20060233778A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO322292B1 (no) | Primaer emballasje inneholdende en vandig opplosning for parenteral administrasjon, fremgangsmate for fremstilling av emballasjen, og anvendelse av en gummiforsegling for denne | |
| EP3606504B1 (en) | Stable antibody formulation | |
| US9193801B2 (en) | Stabilized formulations containing anti-PCSK9 antibodies | |
| CA3162569A1 (en) | Stable antibody formulation | |
| AU2003200467B2 (en) | Improved stability for injection solutions | |
| MXPA01001930A (en) | Improved stability for injection solutions | |
| NZ619379B2 (en) | Stabilized formulations containing anti-pcsk9 antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |